These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 33329607)

  • 1. Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection.
    Russell MW; Moldoveanu Z; Ogra PL; Mestecky J
    Front Immunol; 2020; 11():611337. PubMed ID: 33329607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases.
    Carsetti R; Zaffina S; Piano Mortari E; Terreri S; Corrente F; Capponi C; Palomba P; Mirabella M; Cascioli S; Palange P; Cuccaro I; Milito C; Zumla A; Maeurer M; Camisa V; Vinci MR; Santoro A; Cimini E; Marchioni L; Nicastri E; Palmieri F; Agrati C; Ippolito G; Porzio O; Concato C; Onetti Muda A; Raponi M; Quintarelli C; Quinti I; Locatelli F
    Front Immunol; 2020; 11():610300. PubMed ID: 33391280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection.
    Fröberg J; Diavatopoulos DA
    Curr Opin Infect Dis; 2021 Jun; 34(3):181-186. PubMed ID: 33899752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals.
    Butler SE; Crowley AR; Natarajan H; Xu S; Weiner JA; Bobak CA; Mattox DE; Lee J; Wieland-Alter W; Connor RI; Wright PF; Ackerman ME
    Front Immunol; 2020; 11():618685. PubMed ID: 33584712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced SARS-CoV-2 neutralization by dimeric IgA.
    Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Viant C; Gaebler C; Cipolla M; Hoffmann HH; Oliveira TY; Oren DA; Ramos V; Nogueira L; Michailidis E; Robbiani DF; Gazumyan A; Rice CM; Hatziioannou T; Bieniasz PD; Caskey M; Nussenzweig MC
    Sci Transl Med; 2021 Jan; 13(577):. PubMed ID: 33288661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients.
    Schwarz T; Heiss K; Mahendran Y; Casilag F; Kurth F; Sander LE; Wendtner CM; Hoechstetter MA; Müller MA; Sekul R; Drosten C; Stadler V; Corman VM
    Front Immunol; 2021; 12():629185. PubMed ID: 33833755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.
    Wang B; Wang L; Kong X; Geng J; Xiao D; Ma C; Jiang XM; Wang PH
    J Med Virol; 2020 Sep; 92(9):1684-1689. PubMed ID: 32343415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS-CoV-2 infection.
    Rodríguez-Argente F; Alba-Domínguez M; Ortiz-Muñoz E; Ortega-González Á
    Scand J Immunol; 2021 Jan; 93(1):e12972. PubMed ID: 32892403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplexed analysis of circulating IgA antibodies for SARS-CoV-2 and common respiratory pathogens in COVID-19 patients.
    Fang ZF; Sun BQ; Zhu AR; Lin LC; Zhao JC; He S; Huang SK; Zhong NS; Liu ZG
    J Med Virol; 2021 May; 93(5):3257-3260. PubMed ID: 33506974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgA dominates the early neutralizing antibody response to SARS-CoV-2.
    Sterlin D; Mathian A; Miyara M; Mohr A; Anna F; Claër L; Quentric P; Fadlallah J; Devilliers H; Ghillani P; Gunn C; Hockett R; Mudumba S; Guihot A; Luyt CE; Mayaux J; Beurton A; Fourati S; Bruel T; Schwartz O; Lacorte JM; Yssel H; Parizot C; Dorgham K; Charneau P; Amoura Z; Gorochov G
    Sci Transl Med; 2021 Jan; 13(577):. PubMed ID: 33288662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.
    Mariën J; Ceulemans A; Michiels J; Heyndrickx L; Kerkhof K; Foque N; Widdowson MA; Mortgat L; Duysburgh E; Desombere I; Jansens H; Van Esbroeck M; Ariën KK
    J Virol Methods; 2021 Feb; 288():114025. PubMed ID: 33227340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis.
    Indenbaum V; Koren R; Katz-Likvornik S; Yitzchaki M; Halpern O; Regev-Yochay G; Cohen C; Biber A; Feferman T; Cohen Saban N; Dhan R; Levin T; Gozlan Y; Weil M; Mor O; Mandelboim M; Sofer D; Mendelson E; Lustig Y
    PLoS One; 2020; 15(11):e0241164. PubMed ID: 33227020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.
    Schlesinger T; Weißbrich B; Wedekink F; Notz Q; Herrmann J; Krone M; Sitter M; Schmid B; Kredel M; Stumpner J; Dölken L; Wischhusen J; Kranke P; Meybohm P; Lotz C
    PLoS One; 2020; 15(11):e0242917. PubMed ID: 33232382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Nasal Mucosal Secretions, Distinct IFN and IgA Responses Are Found in Severe and Mild SARS-CoV-2 Infection.
    Dos Santos JMB; Soares CP; Monteiro FR; Mello R; do Amaral JB; Aguiar AS; Soledade MP; Sucupira C; De Paulis M; Andrade JB; Almeida FJ; Sáfadi MAP; Mau LB; Brasil JM; Ramalho T; Loures FV; Vieira RP; Durigon EL; de Oliveira DBL; Bachi ALL
    Front Immunol; 2021; 12():595343. PubMed ID: 33717074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
    Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
    Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.
    Secchi M; Bazzigaluppi E; Brigatti C; Marzinotto I; Tresoldi C; Rovere-Querini P; Poli A; Castagna A; Scarlatti G; Zangrillo A; Ciceri F; Piemonti L; Lampasona V
    J Clin Invest; 2020 Dec; 130(12):6366-6378. PubMed ID: 32991329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual lateral flow optical/chemiluminescence immunosensors for the rapid detection of salivary and serum IgA in patients with COVID-19 disease.
    Roda A; Cavalera S; Di Nardo F; Calabria D; Rosati S; Simoni P; Colitti B; Baggiani C; Roda M; Anfossi L
    Biosens Bioelectron; 2021 Jan; 172():112765. PubMed ID: 33126179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection.
    Quinti I; Mortari EP; Fernandez Salinas A; Milito C; Carsetti R
    Front Cell Infect Microbiol; 2021; 11():655896. PubMed ID: 33889552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.